Skip to main content Skip to navigation
FITC Mouse Anti-Human CD33
FITC Mouse Anti-Human CD33
Flow cytometric analysis of CD33 expression on human peripheral blood leukocytes. Human whole blood was stained with either FITC Mouse Anti-Human CD33 (Cat. No. 555626/561818; solid line histogram) or FITC Mouse IgG1, κ Isotype Control (Cat. No. 555748; dashed line histogram). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Fluorescent histograms were derived from gated events with the forward and side light-scattering characteristics of viable monocytes (Left Panel) or granulocytes (Right Panel). Flow cytometry was performed on a BD FACScan™ system.
Flow cytometric analysis of CD33 expression on human peripheral blood leukocytes. Human whole blood was stained with either FITC Mouse Anti-Human CD33 (Cat. No. 555626/561818; solid line histogram) or FITC Mouse IgG1, κ Isotype Control (Cat. No. 555748; dashed line histogram). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Fluorescent histograms were derived from gated events with the forward and side light-scattering characteristics of viable monocytes (Left Panel) or granulocytes (Right Panel). Flow cytometry was performed on a BD FACScan™ system.
Product Details
Down Arrow Up Arrow


BD Pharmingen™
Siglec-3; SIGLEC3; gp67; p67
Human (QC Testing)
Mouse IgG1, κ
Flow cytometry (Routinely Tested)
20 µl
V MA112
945
AB_395992
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with FITC under optimum conditions, and unreacted FITC was removed.

Product Notices

  1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
  2. An isotype control should be used at the same concentration as the antibody of interest.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
  5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
555626 Rev. 9
Antibody Details
Down Arrow Up Arrow
HIM3-4

The HIM3-4 monoclonal antibody specifically binds to CD33 which is also known as Sialic acid-binding Ig-like lectin 3 (Siglec-3), gp67, or p67. CD33 is a 67 kDa type I transmembrane glycoprotein expressed on monocytes, activated T cells, myeloid progenitors as well as mast cells. CD33 is absent on normal platelets, lymphocytes, erythrocytes and hematopoietic stem cells. This glycoprotein can reportedly function as a sialic acid-dependent cell adhesion molecule. This function can be modulated by endogenous sialoglycoconjugates when CD33 is expressed on the membrane. HIM3-4 reacts with human and monkey granulocytes and monocytes.

555626 Rev. 9
Format Details
Down Arrow Up Arrow
FITC
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
FITC
Blue 488 nm
494 nm
518 nm
555626 Rev.9
Citations & References
Down Arrow Up Arrow
View product citations for antibody "555626" on CiteAb

Development References (7)

  1. Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H. Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol. 1988; 69(2):163-171. (Biology). View Reference
  2. Favaloro EJ, Moraitis N, Koutts J, Exner T, Bradstock KF. Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thromb Haemost. 1989; 61(2):217-224. (Biology). View Reference
  3. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood. 1995; 85(8):2005-2012. (Biology). View Reference
  4. Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182.
  5. Nakamura Y, Noma M, Kidokoro M, et al. Expression of CD33 antigen on normal human activated T lymphocytes.. Blood. 1994; 83(5):1442-3. (Biology). View Reference
  6. Peiper SC, Andrews RG. CD33 cluster workshop report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:837-840.
  7. Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
View All (7) View Less
555626 Rev. 9

 

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.